Boothbay Fund Management LLC Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Posted by on Mar 4th, 2023

Boothbay Fund Management LLC lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 69.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,974 shares of the medical equipment provider’s stock after selling 8,826 shares during the quarter. Boothbay Fund Management LLC’s holdings in Lantheus were worth $279,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC increased its position in Lantheus by 82.1% during the 3rd quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 165 shares in the last quarter. Wipfli Financial Advisors LLC purchased a new stake in Lantheus in the 3rd quarter valued at about $30,000. Focused Wealth Management Inc purchased a new stake in Lantheus in the 3rd quarter valued at about $63,000. Financial Gravity Asset Management Inc. purchased a new stake in Lantheus in the 2nd quarter valued at about $2,319,000. Finally, Quadrant Capital Group LLC grew its holdings in Lantheus by 435.6% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,473 shares of the medical equipment provider’s stock valued at $104,000 after buying an additional 1,198 shares during the period. Hedge funds and other institutional investors own 97.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on LNTH. SVB Leerink began coverage on Lantheus in a report on Wednesday, November 30th. They issued an “outperform” rating for the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Monday, February 27th. Finally, Mizuho lifted their price target on Lantheus from $105.00 to $115.00 and gave the company a “buy” rating in a report on Friday, February 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.80.

Lantheus Stock Performance

NASDAQ LNTH opened at $72.94 on Friday. The firm has a market capitalization of $4.93 billion, a P/E ratio of 214.53 and a beta of 0.64. Lantheus Holdings, Inc. has a 1-year low of $47.46 and a 1-year high of $87.47. The company has a debt-to-equity ratio of 1.25, a current ratio of 2.74 and a quick ratio of 2.59. The business’s 50-day simple moving average is $57.34 and its 200-day simple moving average is $64.51.

Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings data on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.41. The business had revenue of $263.17 million for the quarter, compared to analyst estimates of $244.61 million. Lantheus had a return on equity of 51.60% and a net margin of 3.00%. Equities analysts predict that Lantheus Holdings, Inc. will post 4.46 EPS for the current year.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Read More

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.